<DOC>
	<DOC>NCT00628251</DOC>
	<brief_summary>The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.</brief_summary>
	<brief_title>Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Advanced ovarian cancer with positive BRCA1 or BRCA2 status Progressive or recurrent disease after platinumbased chemotherapy Measurable disease by RECIST Previous anthracycline treatment Brain metastases Less than 28 days since last treatment used to treat the disease Considered a poor medical risk due to a serious uncontrolled disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Advanced ovarian cancer</keyword>
	<keyword>BRCA1 protein</keyword>
	<keyword>BRCA2 protein</keyword>
	<keyword>Poly(ADP ribose) polymerases</keyword>
</DOC>